Flow cytometric analysis on cross-reactivity of human-specific CD monoclonal antibodies with splenocytes of <em>Aotus nancymaae</em>, a non-human... (Publications)
to explore complex host-pathogen interactions in non-human primate animal models, particularly in malaria vaccine research
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents (Publications)
mice. The optimized compounds were found to be more efficacious than the current antimalarials in a malaria mouse model. They exhibit moderate oral exposure in rat pharmacokinetic studies to achieve sufficient
<em>Plasmodium</em> sensitivity to artemisinins: magic bullets hit elusive targets (Publications)
the genetic basis of laboratory-induced or field-observed altered susceptibility is crucial for malaria control. In this review different models of artemisinins' molecular action are briefly presented
Eric Huber (People)
https://www.swisstph.ch/de/staff/profile/people/eric-huber
monitoring of trials, mainly in resource-limited countries, focusing on neglected diseases such as malaria, tuberculosis and helminth infections. Through this work he has gained extensive experience in the
A Tireless Leader (Page)
https://www.swisstph.ch/de/news/20160601-a-tireless-leader
now represented in leading consortia for global health such as the Roll Back Malaria Partnership, the Medicines for Malaria Venture (MMV), the Drugs for Neglected Diseases initiative (DNDi) and the Bill [...] Many return to their country of origin and continue the fight against diseases of poverty such as malaria, tuberculosis and HIV/AIDS in leading functions in health care. “Educating young people from the [...] : all possible means will have to be mobilised in the fight against diseases of...
Declining burden of <em>Plasmodium vivax</em> in a population in northwestern Thailand from 1995 to 2016 before comprehensive primaquine prescription... (Publications)
and artemisinin-based therapy, species-specific diagnostics, and bed net usage all of which reduce malaria transmission but not P. vivax relapse. In the absence of widespread primaquine use for radical cure
Repurposing know-how for drug development: case studies from the Swiss Tropical and Public Health Institute (Publications)
of neglected tropical diseases and other infectious diseases of poverty, such as schistosomiasis, malaria and human African trypanosomiasis.
Evaluation of ethnobotanically selected Benin medicinal plants for their in vitro antiplasmodial activity (Publications)
Twenty extracts from nine Benin medicinal plants, traditionally used to treat malaria, were screened for in vitro antiplasmodial activity towards Plasmodium falciparum K1 chloroquine resistant and 3D7
Vector-borne diseases in humans and animals: activities of the Swiss Tropical Institut and risks for Switzerland (Publications)
This overview presents the Swiss Tropical Institute's (STI) activities on vector-borne diseases (malaria, trypanosomosis, and leishmaniosis in humans and tick-borne diseases in livestock), describes the
Discovery of a quinoline-4-carboxamide derivative with a novel mechanism of action, multistage antimalarial activity, and potent in vivo efficacy (Publications)
pharmacokinetic profile led to several compounds showing excellent oral efficacy in the P. berghei malaria mouse model with ED90 values below 1 mg/kg when dosed orally for 4 days. The favorable potency,
